# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Josh Schimmer reiterates Janux Therapeutics (NASDAQ:JANX) with a Overweight and maintains $100 pri...
Stifel analyst Bradley Canino initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Buy rating and announces Price T...
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Janux Therapeutics (NASDAQ:JANX) with a Buy and maintains ...
Scotiabank analyst George Farmer maintains Janux Therapeutics (NASDAQ:JANX) with a Sector Perform and lowers the price targe...
Cantor Fitzgerald analyst Josh Schimmer reiterates Janux Therapeutics (NASDAQ:JANX) with a Overweight and maintains $100 pri...
Wedbush analyst Robert Driscoll reiterates Janux Therapeutics (NASDAQ:JANX) with a Outperform and maintains $74 price target.
Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(...